- Visibility8
- Citations2
- Sentiment50
- Site quality80
- AI readiness21
AI assistants rarely name Aethlon Medical, mentioning it in 1 of 60 answers about the healthcare market. Its overall score is 29 out of 100, ranking 1,330th of 2,047 companies. The company's website passes 3 of 14 technical checks for readiness for AI tools.
We asked 15 unbranded questions about the healthcare market: none named Aethlon Medical. AI assistants named it in 1 of 60 answers (1.7%). The typical healthcare company is named in 3.3% of answers. By how often it is named, Aethlon Medical ranks 56 of 105 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“What are the most promising clinical-stage immunotherapeutic devices for cancer patients?”
The most promising clinical-stage immunotherapeutic devices for cancer in the results you provided are few in number; the clearest device-stage candidate is Aethlon Medical’s Hemopurifier, a clinical-stage immunotherapeutic device being developed to remove circulating tumor-derived exosomes and other pathogenic targets from blood.
Hemopurifier (Aethlon Medical) — This is the strongest match to your question because multiple sources describe it as a clinical-stage immunotherapeutic device aimed at cancer, including claims that it removes tumor-deri …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 0: Not yet agent-ready. Agents struggle to find basic information about the site.
- 2 of robots.txt, Sitemap, Link headers
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtNot met
Publish a valid robots.txt with crawl rules and a Sitemap line.
- study: 86.8%SitemapPartly met
Serve an XML sitemap and reference it from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesNot met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 7 of 100 · 97% of checks could run · checked on October 5, 2026 · www.aethlonmedical.com · 2,047 companies scanned
3 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- Not metHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotpartly
- ClaudeBotpartly
- Anthropic-AIpartly
- Google-Extendedpartly
- Applebot-Extendedpartly
- Meta-ExternalAgentpartly
- FacebookBotpartly
- Bytespiderpartly
- CCBotpartly
- Diffbotpartly
- Omgilibotpartly
- OAI-SearchBotpartly
- Claude-SearchBotpartly
- PerplexityBotpartly
- Applebotpartly
- Amazonbotpartly
- YouBotpartly
- ChatGPT-Userpartly
- Claude-Userpartly
- Perplexity-Userpartly
- DuckAssistBotpartly
- MistralAI-Userpartly
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as US-listed.
- Which emerging therapies help address unmet needs in infectious disease treatment?
- Is it worth considering a clinical-stage device that removes pathogenic targets from blood for advanced cancer care?
- What are the latest developments in device-based immunotherapy for life-threatening diseases?
- Are there non-invasive options for targeting circulating viral pathogens in severe infections?
- What are the expected costs for advanced blood filtration therapies used in oncology trials?
- What alternatives exist to immunotherapeutic blood filtration devices for cancer patients?
- How much do clinical-stage extracorporeal immunotherapeutic devices typically cost in the US?
- How to address concerns about adverse reactions during extracorporeal immunotherapy procedures?
- How do immunotherapeutic medical devices compare with antibody therapies for treating viral infections?
- How might an investigational immunotherapeutic device be used alongside standard cancer treatments?
- What is the difference between extracorporeal removal devices and traditional chemotherapy for oncology patients?
- What should clinicians look for in new immunotherapeutic technologies for managing life-threatening infections?
- What are the most promising clinical-stage immunotherapeutic devices for cancer patients?
- What are common complications when using innovative blood filtration devices in oncology treatments?
- When is selective removal of circulating viral particles recommended as part of infectious disease management?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.